Cheiron lands $8 million seed for AI-driven development platform

23 July 2026

A young California start-up wants to do for drug development what enterprise software did for accounting and sales: put the whole thing in one connected system. Cheiron, based in Los Altos, has raised $8 million in seed funding to build what it calls an AI-native operating system for drug programs.

The round was led by Menlo Ventures, whose partner Venky Ganesan is joining the board. It drew a striking roster of strategic backers, among them Moderna (Nasdaq: MRNA) co-founder and MIT professor Robert Langer, former Pfizer (NYSE: PFE) chief medical officer Freda Lewis-Hall, and former Apple (Nasdaq: AAPL) artificial intelligence chief John Giannandrea.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK